Clinical Trial

Long-term Safety and Efficacy of Nemolizumab With Moderate-to-severe Atopic Dermatitis

Active, Not Recruiting Phase 3
View on ClinicalTrials.gov →
Summary
Long-Term Safety and Efficacy of Nemolizumab in Subjects with Moderate-to-Severe Atopic Dermatitis Description
Protocol Amendment History 26 amendments
This ClinicalTrials.gov record has been amended 26 times since 2019-06-14; most recent amendment 2024-10-29.
Status change: Enrolling by Invitation → Active, Not Recruiting 2023-08-14
Status change: Recruiting → Enrolling by Invitation 2022-08-01
Status change: Enrolling by Invitation → Recruiting 2020-11-03
Status change: Recruiting → Enrolling by Invitation 2020-06-24
Status change: Not Yet Recruiting → Recruiting 2020-01-26
Trial Details
NCT Number NCT03989206
Lead Sponsor Galderma R&D
Conditions Moderate-to-Severe Atopic Dermatitis
Enrollment 1,700 participants
Start Date 2019-12-30
Primary Completion 2026-08-31 (estimated)
Study Completion 2026-08-31 (estimated)
Updated on ClinicalTrials.gov 2024-10-30